Evasion of apoptosis in pediatric acute lymphoblastic leukemia (ALL) is linked to aberrant expression of inhibitor of apoptosis (IAP) proteins and dysregulated redox homeostasis, rendering leukemic cells vulnerable to redox-targeting therapies. Here we discover that inhibition of antioxidant defenses via glutathione (GSH) depletion by buthionine sulfoximine (BSO) primes ALL cells for apoptosis induced by the Smac mimetic BV6 that antagonizes IAP proteins. Similarly, BSO cooperates with BV6 to induce cell death in patient-derived primary leukemic samples, underscoring the clinical relevance. In contrast, BSO does not sensitize non-malignant lymphohematopoietic cells from healthy donors toward BV6, pointing to some tumor selectivity. Mechanistically, both agents cooperate to stimulate reactive oxygen species (ROS) production, which is required for BSO/BV6-induced cell death, as ROS inhibitors (that is, N-acetylcysteine, MnTBAP, Trolox) significantly rescue cell death. Further, BSO and BV6 cooperate to trigger lipid peroxidation, which is necessary for cell death, as genetic or pharmacological blockage of lipid peroxidation by GSH peroxidase 4 (GPX4) overexpression or α-tocopherol significantly inhibits BSO/BV6-mediated cell death. Consistently, GPX4 knockdown or GPX4 inhibitor RSL3 enhances lipid peroxidation and cell death by BSO/BV6 cotreatment. The discovery of redox regulation of Smac mimetic-induced cell death has important implications for developing rational Smac mimetic-based combination therapies.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) represents the most common childhood malignancy. 1 Besides the overall encouraging cure rate, ALL patients with very high-risk or relapsed disease still bear a poor prognosis. 1, 2 Treatment resistance is often caused by evasion of programmed cell death, as most antileukemic agents primarily act by initiating cell death in leukemic blasts. 3, 4 One of the best characterized forms of programmed cell death is apoptosis. Apoptosis comprises two major pathways, that is, the death receptor (extrinsic) and the mitochondrial (intrinsic) pathway, and eventually leads to activation of caspases. 5 Signaling to apoptosis can be blocked by IAP proteins via inhibition of caspases. 6 In addition, cellular inhibitor of apoptosis (cIAP)1 and cIAP2 function as E3 ubiquitin ligases and can alter signal transduction via K63-linked ubiquitination. 6 Although ubiquitination of the serine/threonine kinase receptor-interacting protein 1 (RIP1) promotes nuclear factor kappaB activation, deubiquitination of RIP1 favors its interaction with Fas-associated protein with death domain (FADD) and caspase-8 to form a cytosolic cell death complex that drives activation of caspase-8. 6 Aberrant expression of X-linked IAP protein (XIAP) has been linked to poor outcome in childhood acute leukemia. 7 Furthermore, high levels of cIAP1 were found in pediatric acute leukemia samples. 8 Small-molecule inhibitors of IAP proteins, so-called Smac mimetics, have been reported to trigger cell death in various cancers by antagonizing XIAP and cIAP proteins. [9] [10] [11] However, there is mounting evidence showing that Smac mimetics as single agents might exert potent antitumor activity only in a small proportion of human cancers, highlighting the need to develop rational combination therapies. 6 Cell death and survival pathways are tightly regulated by the cellular redox state. 12 Redox homeostasis in leukemic cells has been reported to be dysregulated both by an increase in reactive oxygen species (ROS) due to, for example, oncogene activation and by a concomitant upregulation of antioxidant pathways to detoxify high ROS levels. 13 Major antioxidant defense mechanisms for the elimination of ROS comprise reduced glutathione (GSH), the most abundant non-protein thiol and ROS-scavenging enzymes such as thioredoxin and catalase. 14 ROS production in close proximity to lipid membranes causes lipid peroxidation, which has been implied as a critical event during ROS-mediated cancer cell death. 15, 16 Protection against lipid peroxidation is provided by GSH peroxidase 4 (GPX4), the only GPX that is able to reduce hydroperoxides within membranes. 17 As GSH is an essential cofactor of GPXs, GSH depletion has been shown to impair GPX4 function. 18 The increase in basal ROS levels renders cancer cells highly dependent on antioxidant systems and therefore vulnerable to agents that block ROS detoxifying mechanisms. As high intracellular GSH levels have been linked to treatment resistance in leukemia cells, 19, 20 targeting elevated ROS levels has been proposed as a therapeutic opportunity. 21 For example, GSH levels can be depleted by buthionine sulfoximine (BSO), a specific inhibitor of γ-glutamylcysteine ligase, 22 the rate-limiting enzyme in GSH synthesis. Given the important role of redox mechanisms in controlling cell death, our present study investigates the question whether targeting the cellular redox homeostasis can be exploited to potentiate Smac mimetic-induced cell death in ALL cells.
RESULTS

BSO primes ALL cells for BV6-induced cell death
To investigate redox regulation of Smac mimetic-induced cell death in ALL, we blocked a key antioxidant defense pathway via depletion of GSH using BSO. We used a panel of ALL cell lines, including both the T-cell subtype (Jurkat, and the B-cell precursor subtype (Reh, Nalm, Tanoue), as well as the Smac mimetic BV6 that has been shown to antagonize cIAP1, cIAP2 and XIAP. 9 Importantly, BSO acted in concert with BV6 to trigger cell death in T-cell and B-cell precursor ALL cell lines in a concentration-dependent manner (Figure 1a ). Calculation of combination index (CI) values revealed that the drug interaction of BSO and BV6 is highly synergistic at different doses (Supplementary Table 1 ). We confirmed the cooperative induction of cell death by BSO/BV6 combination treatment using flow cytometric analysis of DNA fragmentation and Annexin-V staining as two alternative cell death assays ( Supplementary  Figure 1 ). In addition to these short-time assays, we also performed long-term survival assay. Of note, BSO and BV6 cooperated to significantly reduce clonogenic survival ( Figure 1b ) as well as the number of leukemic cells after 7 days of culture ( Supplementary Figure 2) .
To exclude the possibility that the results shown are specific for BV6, we extended our experiments to other small-molecule Smac mimetics. Similarly, BSO acted in concert with three additional Smac mimetics to trigger apoptosis in ALL cells (Supplementary Figure 3 ). Furthermore, we investigated the question whether inhibition of the thioredoxin pathway, as another cellular antioxidant system besides GSH, enhances BV6-induced cell death. Auranofin, an inhibitor of thioredoxin reductase 14 significantly increased BV6-induced cell death ( Supplementary Figure 4) .
To explore the potential clinical relevance of the BSO/BV6 combination treatment, we extended our study to primary ALL samples derived from children with ALL before the start of chemotherapy (Supplementary Table 2 ). Importantly, BSO synergized with BV6 to induce cell death in freshly isolated leukemic blasts in a dose-dependent manner (Figure 1c ).
To examine whether the BSO/BV6 combination treatment preferentially affects malignant versus non-malignant cells, we performed experiments with non-malignant cell types of the lymphohematopoietic system, using peripheral blood lymphocytes (PBLs) and mesenchymal stromal cells (MSCs) that were freshly isolated from healthy donors. Notably, BSO did not enhance BV6-induced cell death in PBLs or MSCs at equimolar concentrations of BSO and BV6 that synergized to induce cell death in ALL cells (Figures 1d and e ). This set of experiments shows that the GSH-depleting agent BSO and the Smac mimetic BV6 synergistically trigger cell death in ALL cells including primary leukemic blasts, whereas it does not increase BV6-induced cytotoxicity against non-malignant cells of the lymphohematopoietic system. ROS production is required for BSO/BV6-induced cell death As depletion of intracellular GSH levels has been described to facilitate the generation of ROS, 14 we hypothesized that the BSOmediated sensitization for BV6-induced cell death involves alterations of the cellular redox state. To address this point, we determined cellular GSH levels and GSH/GSSG ratio in cells before they succumb to cell death, that is, in propidium iodide (PI)negative cells at early time points of the cell death kinetic (Supplementary Figure 5 ) to ensure that these events precede the induction of cell death. As expected, treatment with BSO alone and in combination with BV6 reduced GSH levels and GSH/GSSG ratio in ALL cells (Figure 2a ; Supplementary Figure 6A ). By comparison, treatment with BSO and/or BV6 had little effects on GSH levels in MSCs (Supplementary Figure 6B ).
Next we assessed cellular ROS levels in PI-negative cells using the fluorescent dye CM-H 2 DCFDA and flow cytometry. Interestingly, BSO acted together with BV6 to significantly enhance ROS production compared with either treatment alone ( Figure 2b ). Cellular ROS production by BSO/BV6 cotreatment in PI-negative cells was confirmed by using CellROX as another ROS-sensitive fluorescent dye ( Figure 2c ). We also noticed that BV6 as a single agent led to cellular ROS production, a finding that was corroborated by dose-response experiments (Figure 2c ; Supplementary Figure 7 ). Increased ROS production on treatment with BV6 alone or in combination with BSO was also detected by MitoSOX ( Supplementary Figure 8) , a ROS-sensitive dye that has been reported to preferentially detect mitochondrial ROS. 23 To explore whether ROS production is required for BSO/BV6-induced cell death, we used different ROS scavengers including Nacetylcysteine (NAC), a biosynthetic precursor to GSH, 12 MnTBAP, a cell-permeable SOD mimetic with catalase-like activity 24 and Trolox, a soluble vitamin E derivate. 25 Of note, the addition of NAC, MnTBAP or Trolox significantly reduced BSO/BV6-induced ROS production and cell death (Figure 2d ; Supplementary Figure 9 ). The higher potency of NAC compared with MnTBAP or Trolox to protect against BSO/BV6-mediated ROS production and cell death might be due to its ability as biosynthetic precursor of GSH to counteract GSH depletion by BSO. Also, NAC significantly increased clonogenic survival on treatment with BSO/BV6 (Supplementary Figure 10 ). Moreover, BSO/BV6-stimulated ROS production correlated with the induction of cell death (Supplementary Figure 11 ), further supporting the notion that ROS production is required for BSO/BV6-induced cell death.
Lipid peroxidation mediates BSO/BV6-induced cell death As NAC, MnTBAP and Trolox have been described to scavenge ROS species, which can initiate radical chain reactions with membrane lipids leading to the generation of lipid peroxides, [26] [27] [28] [29] we hypothesized that lipid peroxides mediate BSO/BV6-induced cell death. To test this hypothesis, we assessed lipid peroxidation in PI-negative cells, that is, in cells before they succumb to cell death, by staining cells with the fluorescent dye BODIPY-C11, a membrane-targeted lipid ROS sensor. 30 Importantly, BV6 and BSO acted in concert to cause lipid peroxidation as indicated by a shift in fluorescence intensity ( Figure 3a ). To investigate whether lipid peroxidation is required for cell death induction, we used αtocopherol, a pharmacological inhibitor of lipid peroxidation. 31 Interestingly, the addition of α-tocopherol prevented the BSO/ BV6-induced lipid peroxidation ( Figure 3b ) and significantly reduced BSO/BV6-triggered cell death ( Figure 3c ). Also, αtocopherol significantly rescued BSO/BV6-induced loss of clonogenic survival (Supplementary Figure 10 ). This indicates that BSO and BV6 cooperate to stimulate lipid peroxidation, which is required for BSO/BV6-induced cell death.
GPX4 rescues BSO/BV6-induced lipid peroxidation and cell death
To further investigate the requirement of lipid peroxidation for BSO/BV6-induced cell death, we used genetic and pharmacological approaches to modulate expression or activity of GPX4, as GPX4 is known to specifically catalyze the reduction of lipid peroxides. 17 Importantly, overexpression of GPX4 significantly reduced BSO/BV6-induced ROS production, lipid peroxidation and cell death (Figures 4a-c; Supplementary Figure 12 ). Consistently, GPX4 knockdown significantly increased lipid peroxidation and cell death on BSO/BV6 stimulation compared with non-silencing control (Figures 4d-f ). In addition, we investigated the involvement of GPX1, which has been reported to reduce soluble hydroperoxides but not phospholipid peroxides. 17 Overexpression of GPX1 partially reduced BSO/BV6-induced cell death without affecting ROS production ( Supplementary Figure 13) , indicating that additional ROS species that are not scavenged by GPX1 such as lipid peroxides contribute to BSO/BV6-induced cell death. Furthermore, RSL3, a recently described pharmacological inhibitor of GPX4, 18 acted in concert with BV6 to trigger cell death ( Figure 4g ). We also used erastin as an alternative pharmacological approach to deplete GSH. Erastin inhibits GSH synthesis by blocking cysteine uptake via inhibition of system x c − , a cysteine/ glutamate amino acid transporter at the plasma membrane. 32 As GSH is an essential cofactor of GPXs, 17 erastin inhibits GPX4 similar to BSO. In line with its mode of action, erastin cooperated with BV6 to induce cell death ( Figure 4h ). These findings underscore that lipid peroxidation is a critical event in mediating BSO/BV6induced cell death.
As GPX4 and lipid peroxidation have recently been implicated in the regulation of ferroptosis, an iron-dependent non-apoptotic form of cell death, 18, 32 we investigated whether BSO/BV6-induced cell death is mediated by ferroptotic pathways. To this end, we used iron-chelating compounds such as deferoxamine and ferrostatin-1, which were previously reported to block ferroptosis. 32 However, deferoxamine and ferrostatin-1 largely failed to abrogate BSO/BV6-induced cell death, as only ferrostatin-1 partially reduced cell death by BSO/BV6 in one of two tested cell lines (Supplementary Figure 14) . In contrast, deferoxamine and ferrostatin-1 significantly inhibited ferroptotic cell death by RSL3 ( Supplementary Figure 14) , which was used as a positive control. 18 This set of experiments indicates that BSO/BV6-induced cell death is largely iron independent and therefore can not be classified as ferroptosis.
RIP1, FADD and caspase-8 are required for BSO/BV6-induced ROS production, lipid peroxidation and cell death We previously reported that Smac mimetic-mediated depletion of cIAP proteins promotes the assembly of a cytosolic cell death complex containing RIP1, FADD and caspase-8 that drives caspase-8 activation and cell death. [33] [34] [35] [36] Indeed, we observed rapid degradation of cIAP1 and cIAP2 on treatment with BV6 or with BV6 and BSO (Supplementary Figure 15 ). Immunoprecipitation of caspase-8 showed that BSO/BV6 cotreatment stimulated the formation of a RIP1/FADD/caspase-8-containing complex (Figure 5a ). To explore whether this RIP1/FADD/caspase-8 complex is required for ROS production, lipid peroxidation and cell death, we genetically interfered with caspase-8, FADD or RIP1 expression by using caspase-8-or FADD-deficient cells (Figure 5b ) or by RNA interference-mediated knockdown of RIP1 (Figure 5c ; Supplementary Figure 16 ). Interestingly, BSO/BV6-stimulated ROS production was significantly decreased in FADD-or caspase-8deficient cells and in RIP1 knockdown cells compared with corresponding control cells (Figures 5d and e ). Consistently, BSO/ BV6-induced lipid peroxidation was significantly reduced in caspase-8-or FADD-deficient cells and in RIP1 knockdown cells (Figure 5f ). In parallel, caspase-8 and FADD deficiency or RIP1 knockdown significantly protected cells against BSO/BV6-induced cell death (Figures 5g and h) . Similarly, transient small interfering RNA (siRNA)-mediated knockdown of caspase-8 significantly decreased BSO/BV6-stimulated lipid peroxidation and cell death ( Supplementary Figures 17A-C) . By comparison, the caspase-8selective inhibitor N-benzyloxycarbonyl-Ile-Glu-Thr-Asp-fluoromethylketone (zIETD.fmk) did not prevent BSO/BV6-triggered lipid peroxidation and cell death, whereas zIETD.fmk significantly reduced TRAIL-induced cell death used as positive control ( Supplementary Figures 17D-F ), suggesting that caspase-8 protein rather than caspase-8 activity is required for BSO/BV6-mediated lipid peroxidation and cell death. Together, this set of experiments indicates that RIP1, FADD and caspase-8 are required for BSO/BV6induced ROS production, lipid peroxidation and cell death.
Lipid peroxidation promotes BSO/BV6-induced caspase activation As the RIP1/FADD/caspase-8-containing cell death complex has been shown to serve as a platform for caspase-8 activation, [33] [34] [35] [36] we next monitored activation of the caspase cascade by western blotting. We observed that BSO enhanced BV6-induced processing of caspase-8, -9 and -3 into active cleavage fragments as indicated by an increase in the active caspase-8 cleavage products p43/41, caspase-9 cleavage fragment p37 and caspase-3 cleavage products p19/17/12 (Figure 6a ). Addition of the broad-range caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD.fmk) significantly reduced BSO/BV6-induced DNA fragmentation and cell death (Figures 6b and c) , demonstrating that caspase activity is required for the induction of apoptosis. To investigate whether caspase activity is necessary for BSO/BV6induced lipid peroxidation, we determined the production of lipid peroxides on BSO/BV6 stimulation in the presence and absence of zVAD.fmk. BSO/BV6-triggered lipid peroxidation occurred irrespectively of whether or not caspase activity was blocked by zVAD.fmk (Figure 6d ). Vice versa, we also explored whether lipid peroxidation promotes caspase activation. Of note, addition of α-tocopherol attenuated BSO/BV6-induced processing of caspase-8, -9 and -3 into active cleavage fragments ( Supplementary Figure 18 ). This indicates that BSO/BV6-stimulated lipid peroxidation promotes caspase activation, while caspase activity is not required for lipid peroxidation. As RIP1/FADD/caspase-8 complex formation has been implicated in engaging TLR3 signaling, 37 we investigated the potential involvement of TLR3 signaling in BSO/BV6-induced cell death. However, knockdown of TLR3 or TRIF did not alter cell death induced by BSO/BV6 ( Supplementary Figure 19) , indicating that BSO/BV6-mediated cell death occurs independently of TLR3 signaling.
DISCUSSION
Evasion of apoptosis contributes to poor treatment response of pediatric high-risk ALL, highlighting the medical need for novel treatment strategies to augment programmed cell death. 4 Redoxbased regulation of biological processes is increasingly being exploited for cancer therapy. 12, 21 Leukemic cells exhibit elevated ROS levels coupled to increased antioxidant adaptation mechanisms, 13 which renders them vulnerable to redoxtargeting therapies. However, the role of redox signaling in Smac mimetic-induced cell death has not yet been explored.
In this study, we report that inhibition of antioxidant defenses by the GSH-depleting agent BSO primes ALL cells for Smac mimetic-induced apoptosis. Synergistic cell death induction occurs at subtoxic concentrations of both single agents BSO and BV6 as demonstrated by calculation of CI and highlights the potency of this approach. In addition to short-term assays, BV6 do not exhibit any synergistic response to combination treatment pointing to some tumor selectivity. Together, these findings highlight the important role of redox regulation in Smac mimeticinduced cell death and indicate that modulation of the cellular redox state represents a promising approach to potentiate Smac mimetic-based treatment strategies in leukemia. Although modulation of ROS levels via GSH depletion has previously been described to sensitize leukemic cells for death receptor ligands (that is, CD95, TRAIL) or anticancer agents (that is, arsenic trioxide, doxorubicin), 19, 20 our study is the first to demonstrate the relevance of redox signaling, and in particular lipid peroxidation, in the regulation of Smac mimetic-induced cell death, which highlights the novelty of the present study. Furthermore, we elucidate the underlying molecular mechanism of the synergistic interaction of BSO and BV6 (Figure 7 ). We show that both agents act in concert to increase ROS production and lipid peroxidation, which are required for BSO/BV6-induced cell death. This conclusion is supported by several lines of evidence. First, experiments showing that different ROS inhibitors significantly rescue BSO/BV6-induced cell death underline that ROS are necessary for BSO/BV6-triggered cell death. In addition, ROS production closely correlates with cell death on BSO/BV6 treatment. Our data showing that BSO-induced ROS production is primarily detected by CM-H 2 DCFDA, whereas BV6-stimulated ROS generation is mainly detectable using CellROX, suggest that each agent may produce distinct ROS, as CM-H 2 DCFDA is a fluorescent probe that predominately measures hydrogen peroxide, hydroxyl radicals and peroxyl radicals 38 and CellROX has been implicated to detect superoxide radicals. However, as fluorescent probes have limitations in specifying ROS at the molecular level, 39 additional analytical assays would be necessary to accurately characterize the involved species. The notion that GSH depletion by BSO sensitizes for BV6-induced cell death is supported by our experiments using erastin, another GSH-depleting agent, which similarly primes leukemia cells for BV6-mediated cell death. Erastin inhibits system x c − that is required for cellular uptake of cysteine, one of the three amino acids necessary for GSH synthesis. 32 Compared with the critical requirement of ROS for cell death induction, the BSOmediated depletion of intracellular GSH levels per se is not sufficient to initiate cell death programs. This indicates that an additional stimulus besides GSH depletion is necessary to increase ROS production and to initiate cell death. By comparison, GSH depletion independently of ROS accumulation has previously been shown to be sufficient for cell death induction, 40, 41 pointing to a context-dependent regulation of cell death pathways by GSH. Second, by genetic and pharmacological inhibition, we demonstrate that lipid peroxidation is critical for BSO/BV6-induced cell death. Overexpression of GPX4, one of the GPXs that specifically reduces hydroperoxides within membranes, 17 significantly decreases BSO/BV6-mediated lipid peroxidation and cell death. Consistently, ROS scavengers, which can interfere with the lipid peroxidation chain reaction, significantly decrease BSO/BV6stimulated cell death. In addition, NAC acts as a synthetic precursor of GSH, which is necessary for the activity of several antioxidative enzymes such as GPX4. Similarly, α-tocopherol, which has been described to scavenge lipid peroxides, 42 attenuates lipid peroxidation, caspase activation and cell death on BSO/BV6 cotreatment. Vice versa, siRNA-mediated silencing of GPX4 enhances lipid peroxidation and cell death on BSO/BV6 cotreatment. Similarly, pharmacological inhibition of GPX4 using either the GPX4 inhibitor RSL3 18 or erastin, which inactivates GPX4 via depletion of GSH as an essential cofactor of GPXs, 18 sensitizes leukemia cells for BV6-induced cell death. BSO/BV6-stimulated lipid peroxidation is confirmed by stainings with BODIPY-C11, a membrane-targeted lipid ROS sensor that detects lipid peroxides. 38 GPX4 has previously been identified as a critical regulator of cancer cell death by controlling lipid peroxidation, as inhibition of GPX4 expression or activity led to increased lipid peroxidation and cell death. 18, 42 Lipid peroxidation and GPX4 have been implicated in mediating different forms of programmed cell death, 18, 32, 42, 43 possibly in a context-dependent manner. Although genetic overexpression of GPX4 was shown to rescue TNFα-induced generation of lipid peroxides and apoptosis in leukemia cells, 43 GPX4 has recently been identified as a critical regulator of ferroptosis, an iron-dependent form of non-apoptotic cell death that involves lipid peroxidation. 18 As BSO/BV6-induced cell death is not rescued by iron-chelating compounds, it is not consistent with typical features of ferroptosis. Furthermore, RIP3-dependent ROS production on treatment with a Smac mimetic compound was reported to promote ubiquitination and activation of caspase-8, which was associated with its sequestration into detergentresistant membranes. 44 Caspase-8 ubiquitination has previously been described to be required for its sequestration into lipid raft membranes and its full activation. 45 Our key finding showing that BSO and BV6 synergize to trigger ROS production, lipid peroxidation and cell death in leukemic cells underscores that both antioxidant pathways and ROS levels have critical roles in maintaining the redox balance in ALL cells. The GSH system as one of the main cellular antioxidant defenses provides a connection between ROS and lipid peroxidation in two ways: first, GSH depletion promotes ROS production and ROSmediated lipid peroxidation by decreasing the cell's antioxidant capacity. Second, GSH depletion favors lipid peroxidation by reducing the enzyme activity of GPX4, as GSH is an essential cofactor of GPX4. 18 Our study has important implications for the development of Smac mimetic-based therapies in childhood ALL. The identification of the new synergistic drug interaction of the Smac mimetic BV6 together with GSH-depleting agents such as BSO is particularly relevant for childhood ALL, as leukemic cells have been reported to harbor high levels of both IAP proteins and ROS. 13, 46, 47 In addition, poor treatment response in pediatric acute leukemia has been linked to aberrant expression levels of IAP proteins 6, 7, 48 as well as elevated levels of GSH. 49, 50 The feasibility to transfer this Smac mimetic/BSO combination strategy into clinical application is underscored by the fact that Smac mimetic as well as BSO are currently already under clinical evaluation. 51, 52 In addition, the BSO concentrations that were required for synergism with BV6 might be clinically achievable in humans, as plasma concentrations have been reported in the range of 0.5-1.5 mM BSO. 53 Further, there might be a therapeutic window for the combined use of Smac mimetic and BSO given the observed preferential sensitization of malignant leukemic cells, but not non-malignant PBLs or MSCs for BV6-induced cell death. This therapeutic selectivity might be explained by higher ROS levels that have consistently been reported in leukemic blasts compared with normal cells. 13 In summary, the discovery showing that Smac mimetic-induced cell death is regulated via redox mechanisms opens new perspectives for the development of rational combination treatments and, thus, has important implications for childhood ALL.
MATERIALS AND METHODS
Cell culture and chemicals
Human T-ALL (Jurkat, Molt-4) and precursor (pre)-B-ALL (Reh, Nalm, Tanoue) cell lines were obtained from ATCC (Manassas, VA, USA) or DSMZ (Braunschweig, Germany) and were cultured as described previously. 54 Smac mimetic BV6, which neutralizes XIAP, cIAP1 and cIAP2, 9 was kindly provided by Genentech Inc. (South San Francisco, CA, USA). Leukemic blasts were derived from children with ALL at initial diagnosis before the onset of therapy at the University Children's Hospital Frankfurt, isolated using Ficoll Isopaque (Amersham Bioscience, Freiburg, Germany) and stimulated in X-VIVO Medium (Lonza, Walkersville, MD, USA) supplemented with 10% fetal calf serum and 0.5% penicillin/streptomycin. PBLs were isolated from healthy donors by ficoll separation (Biochrom, Berlin, Germany) and stimulated directly after isolation in X-VIVO Medium. The study was approved by the local ethics committee in accordance with the Declaration of Helsinki. Human MSCs were generated and cultured as previously described. 34 Chemicals were purchased by Sigma (Hamburg, Germany), caspase inhibitor zVAD.fmk from Bachem (Heidelberg, Germany), MnTBAP from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) and RSL3 from InterBIOScreen Ltd. (Moscow, Russia).
Transduction and transfection
Gene silencing by lentiviral shRNA vectors was performed as previously described 55 using pGIPZ-shRNAmir vectors (Thermo Fisher Scientific, Dreieich, Germany): non-silencing control: RHS4346, shRNA-RIP1#1: RHS4430-99891489, shRNA-RIP1#2: RHS4430-101068916. Reh cells with lentiviral knockdown of RIP1 were previously described. 34 For transient knockdown by siRNA, cells were reversely transfected with SilencerSelect siRNA (Invitrogen, Karlsruhe, Germany), control siRNA (4390843) or targeting siRNAs for GPX4 (siGPX4#1: s6111 and siGPX4#2: s6112) or siRNA for RIP1 (siRIP1#1: s16651 and siRIP1#2: s16653) using Neon transfection system (Invitrogen) following the manufacturer's instructions. Transient overexpression of murine GPX4-pcDNA3 construct, kindly provided by R Brigelius-Flohé, 56 was performed by Neon transfection system (Invitrogen).
Western blot analysis
Western blot analysis was performed as described previously 57 using the following antibodies: mouse anti-caspase-8 from Alexis Biochemicals (Epalinges, Switzerland), rabbit anti-caspase-3 (Cell Signaling, Beverly, MA, USA), rabbit anti-caspase-9, mouse anti-XIAP, mouse anti-FADD and mouse anti-RIP1 from BD Biosciences (Heidelberg, Germany), goat anti-cIAP1 and mouse anti-GPX4 from R&D Systems, Inc. (Wiesbaden, Germany), rabbit anti-cIAP2 (Epitomics, Burlingame, CA, USA), mouse anti-β-actin or anti-GAPDH as loading control (Sigma) followed by goat-anti-mouse immunoglobulin G (IgG), goat-anti-rabbit IgG or donkey-anti-goat IgG conjugated to horseradish peroxidase (Santa Cruz Biotechnology). Enhanced chemiluminescence was used for detection (Amersham Bioscience). Alternatively, donkey anti-mouse IgG, donkey anti-rabbit or donkey anti-goat IgG labeled with IRDye infrared dyes were used for fluorescence detection (LI-COR Biotechnology, Bad Homburg, Germany). All western blots shown are representative of at least two independent experiments.
Determination of cell death and long-term survival assay
Apoptosis was determined by flow cytometric analysis (FACSCanto II, BD Biosciences) of DNA fragmentation of PI-stained nuclei, or by forward/ side-scatter analysis as described previously. 57 Cell death of MSCs was determined by measuring loss of plasma membrane integrity by PIemitted fluorescence and flow cytometry. The percentage of specific cell death was calculated as follows: 100 × [experimental cell death (%) − spontaneous cell death (%)]/[100% − spontaneous cell death (%)]. For clonogenic assay, cells were treated with BV6 and/or BSO for 10 h and then seeded in semisolid culture media (H4100, StemCell Technologies, Vancouver, BC, Canada) as previously described. 58 Immunoprecipitation Cells were lysed in NP40 buffer (10 mM Tris (pH 8.0), 150 mM NaCl, 1% Nonidet P-40, supplemented with a protease inhibitor tablet (Roche, Grenzach, Germany). Proteins (2 mg) were incubated with 10 μl mouse anti-caspase-8 antibody (Alexis Biochemicals) overnight at 4°C followed by the addition of 20 μl pan-mouse IgG Dynabeads (Invitrogen), then incubated for at least 2 h at 4°C and washed with NP40 buffer. Caspase-8 was detected using rabbit monoclonal anti-caspase-8 antibody (Epitomics), RIP1 or FADD with anti-mouse RIP1 antibody or mouse-anti-FADD antibody (BD Biosciences). Figure 7 . Scheme of synergistic induction of cell death by BSO/BV6 cotreatment. BV6 triggers the formation of the RIP1/FADD/caspase-8-containing cell death complex via degradation of IAP proteins. BSO depletes GSH by inhibiting γ-glutamylcysteine ligase, the ratelimiting enzyme in GSH synthesis. BSO and BV6 cooperate in ROS production and lipid peroxidation, leading to caspase activation and cell death. The GSH-depleting drug erastin, the GPX4 inhibitor RSL3 or GPX4 knockdown sensitize cells for BV6-induced cell death, whereas inhibitors of ROS production, lipid peroxidation or caspases, genetic deficiency of RIP1, caspase-8 or FADD or overexpression of GPX4 inhibit BV6-mediated cell death. See text for more details.
Determination of intracellular GSH levels, ROS production and lipid peroxidation GSH levels, ROS production and lipid peroxidation were analyzed in PI-negative cells at early time points before cells succumb to cell death to monitor events preceding the induction of cell death. To determine GSH levels, cells were incubated with 0.5 μM monobromobimane (Sigma) for 30 min at 37°C and immediately analyzed by flow cytometry. To analyze ROS production, cells were incubated with CellROX (1 μM; Invitrogen), which primarily detects superoxide radicals according to manufacturer's instructions, or CM-H 2 DCFDA (5 μM, Invitrogen), which has been reported to detect ROS such as hydrogen peroxides, hydroxyl radicals or peroxyl radicals, 38 for 30 min at 37°C and immediately analyzed by flow cytometry. Lipid peroxidation was analyzed after staining with fluorescent dye BODIPY-C11 (5 μM; Invitrogen) for 30 min and immediately analyzed by flow cytometry.
Statistical analysis
Statistical significance was assessed by Student's t-test. Drug interactions were analyzed by the CI method based on that described by Chou 59 using CalcuSyn software (Biosoft, Cambridge, UK). CI o0.9 indicates synergism, 0.9-1.1 additivity and 41.1 antagonism.
